In this Between The Dose bonus episode of The Elevated Dose, I break down the new World Health Organization (WHO) guidelines on GLP-1 medications for obesity and what they mean for people actively using or considering GLP-1 therapy.

This episode explains, in plain language, how the WHO now formally recognizes obesity as a chronic, relapsing disease and endorses GLP-1 receptor agonists as legitimate long-term medical treatment for obesity, not shortcuts or failures of willpower.

We cover:

• ​ What the WHO guidelines actually say about GLP-1 medications for obesity
• ​ Why obesity is now classified as a chronic disease requiring ongoing care
• ​ How GLP-1 drugs like semaglutide and tirzepatide fit into long-term obesity treatment
• ​ Why weight regain after stopping GLP-1 medication is expected biology, not personal failure
• ​ The role of structure, routine, and behavioral support alongside GLP-1 therapy
• ​ The real barriers to GLP-1 access, including cost, insurance, and health-system limitations
• ​ What these guidelines mean for plateaus, slow progress, maintenance, and medication changes

This episode is especially relevant if you are:

• ​ On a GLP-1 and feeling stalled or discouraged
• ​ Navigating maintenance or worried about weight regain
• ​ Considering starting a GLP-1 medication for obesity
• ​ Recovering from years of dieting, medical gaslighting, or shame-based weight loss care

The WHO guidance validates what many people on GLP-1s already know from lived experience: obesity treatment is not about willpower; it’s about biology, access, and sustained medical support.

This episode is educational and based on lived experience. It is not medical advice. Always consult your healthcare provider regarding GLP-1 medications and obesity treatment.

Stay up to date on all things The Elevated Dose at www.theelevateddose.com